Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

A Chinese pharmaceutical company specializing in heparin and other active pharmaceutical ingredients.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

• New cancer drug H1710 enters first human tests Results expected Sep 2026 (estimated)